Literature DB >> 15485418

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.

Nagesh S Anavekar1, Daniel J Gans, Tomas Berl, Richard D Rohde, William Cooper, Amitabha Bhaumik, Lawrence G Hunsicker, Jean-Lucien Rouleau, Julia B Lewis, Clive Rosendorff, Jerome G Porush, Paul L Drury, Enric Esmatjes, Itamar Raz, Phillippe Vanhille, Franceso Locatelli, Samuel Goldhaber, Edmund J Lewis, Marc A Pfeffer.   

Abstract

Individuals with type 2 diabetes and nephropathy represent a particularly high-risk group for both adverse cardiac as well as renal events. Using the Irbesartan in Diabetic Nephropathy Trial (IDNT) cohort, our objective was to determine baseline characteristics of individuals with type 2 diabetic nephropathy and hypertension predictive for cardiac events. IDNT identified 1715 individuals with type 2 diabetic nephropathy and hypertension having serum creatinine of 1.0 to 3.0 mg/dL and urinary albumin excretion rates > or = 900 mg/day. A cardiovascular (CV) composite was used consisting of CV death, nonfatal MI, hospitalization for heart failure, stroke, amputation, and coronary and peripheral revascularization. Using multivariable Cox regression analysis, 41 baseline characteristics determined a priori were analyzed for their potential relationship to risk of experiencing a CV event. Of the 1715 individuals, 518 (30.2%) had at least one of the CV composite end points. Older age, male gender, longer duration of diabetes, history of cardiovascular disease, history of CHF, high urinary albumin:creatinine ratio, and low serum albumin were strong predictors for CV events; of these, prior history of CVD (RR 2.00, 95% CI 1.63-2.45; P < 0.0001) and high urinary albumin:creatinine ratio (RR 1.29 per natural log unit, 95% CI 1.13-1.48; P = 0.0002) at baseline were highly predictive for cardiovascular events. In conclusion, among individuals with hypertension and diabetic nephropathy, both the degree of albuminuria and lower serum albumin levels provide additional prognostic information concerning cardiovascular risk, in addition to traditional coronary risk factors.

Entities:  

Mesh:

Year:  2004        PMID: 15485418     DOI: 10.1111/j.1523-1755.2004.09213.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  28 in total

Review 1.  Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?

Authors:  Michael R Lattanzio; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

2.  Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.

Authors:  Jayanta Gupta; Nandita Mitra; Peter A Kanetsky; Joe Devaney; Maria R Wing; Muredach Reilly; Vallabh O Shah; Vaidyanathapura S Balakrishnan; Nicolas J Guzman; Matthias Girndt; Brian G Periera; Harold I Feldman; John W Kusek; Marshall M Joffe; Dominic S Raj
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

Review 3.  Clinical modifiers for heart failure following myocardial infarction.

Authors:  Nandan S Anavekar; Nagesh S Anavekar
Journal:  Curr Heart Fail Rep       Date:  2005-12

Review 4.  Should albuminuria be a focus of antihypertensive therapy goals?

Authors:  Radica Z Alicic; Sandeep A Saha; Robert A Short; Katherine R Tuttle
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

5.  Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial.

Authors:  Marcello Tonelli; Powell Jose; Gary Curhan; Frank Sacks; Eugene Braunwald; Marc Pfeffer
Journal:  BMJ       Date:  2006-05-19

Review 6.  [Hypertension and the kidney].

Authors:  Katharina Hohenstein; Bruno Watschinger
Journal:  Wien Med Wochenschr       Date:  2008

Review 7.  Cardiovascular implications of proteinuria: an indicator of chronic kidney disease.

Authors:  Varun Agrawal; Victor Marinescu; Mohit Agarwal; Peter A McCullough
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

Review 8.  Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Cardiovascular implications of chronic kidney disease in older adults.

Authors:  Ramnath Dukkipati; Sharon Adler; Rajnish Mehrotra
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

10.  Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events.

Authors:  Cornelis Boersma; Maarten J Postma; Sipke T Visser; Jarir Atthobari; Paul E de Jong; Lolkje T W de Jong-van den Berg; Ron T Gansevoort
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.